We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.81B
1-Year Est. Return
192.15%
This Fund
S&P 500
This Quarter
Est. Return
+9.14%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$727M
AUM Growth
-$47.6M
(-6.1%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-17.69%
Top 10 Holdings %
Top 10 Hldgs %
82.71%
Holding
37
New
2
Increased
11
Reduced
6
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$40.1M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$14.8M |
| 3 |
Cogent Biosciences
COGT
|
+$14M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$12.2M |
| 5 |
Viridian Therapeutics
VRDN
|
+$4.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$119M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$20.2M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$18.6M |
| 4 |
GSK
GSK
|
+$17.7M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.74% |
| 2 | Miscellaneous | 10.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gyre Therapeutics
GYRE
$760M
| $31.6K | ﹤0.01% |
5,992
| – | – |
|
|
ACLX
27
DELISTED
Arcellx
ACLX
| – | – |
-31,336
| Closed | -$965K |
|
28
Allogene Therapeutics
ALLO
$643M
| – | – |
-1,495,981
| Closed | -$7.39M |
|
29
Gossamer Bio
GOSS
$87.9M
| – | – |
-1,502,866
| Closed | -$1.89M |
|
|
30
GSK
GSK
$97.3B
| – | – |
-498,329
| Closed | -$17.7M |
|
|
31
Iovance Biotherapeutics
IOVA
$3.94B
| – | – |
-1,800,000
| Closed | -$11M |
|
32
Seres Therapeutics
MCRB
$55.8M
| – | – |
-38,446
| Closed | -$4.36M |
|
|
MRUS
33
DELISTED
Merus
MRUS
| – | – |
-21,457
| Closed | -$395K |
|
34
Xenon Pharmaceuticals
XENE
$5.77B
| – | – |
-28,696
| Closed | -$1.03M |
|
|
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-499,853
| Closed | -$18.6M |
|
|
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-100,000
| Closed | -$20.2M |
|
|
HZNP
37
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-1,094,620
| Closed | -$119M |
|
Similar funds
AF
RP
LPT
SFG
GA
CCS
PPW
OPCM
Kynam Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Kynam Capital Management held 37 positions worth $727M, down 6.1% from $775M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Kynam Capital Management withdrew a net $129M in Q2 2023, closing 11 positions and reducing 6 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $119M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Kynam Capital Management added an estimated $40.1M to Celldex Therapeutics.
- Kynam Capital Management added most to Celldex Therapeutics in Q2 2023, an estimated $40.1M increase.
- Kynam Capital Management's biggest Q2 2023 reduction was Protagonist Therapeutics, cutting an estimated $10M.
- Kynam Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $119M.
- Kynam Capital Management's ten largest holdings make up 83% of its $727M portfolio in Q2 2023.
- Kynam Capital Management opened 2 new positions and closed 11 in Q2 2023.
- Kynam Capital Management's portfolio value fell 6.1% quarter-over-quarter to $727M.
Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.